Brian D. Juran, Konstantinos N. Lazaridis – 28 November 2006 – The concept of genetic susceptibility in the contribution to human disease is not new. What is new is the emerging ability of the field of genomics to detect, assess, and interpret genetic variation in the study of susceptibility to development of disease. Deciphering the human genome sequence and the publication of the human haplotype map are key elements of this effort.

Elwyn Elias – 28 November 2006

Adrian Reuben – 28 November 2006

Harry L. A. Janssen, Frank W. G. Leebeek – 28 November 2006

Christina Esteva‐Font, Maria E. Baccaro, Patricia Fernández‐Llama, Laia Sans, Monica Guevara, Elisabet Ars, Wladimiro Jiménez, Vicente Arroyo, Jose A. Ballarín, Pere Ginès – 28 November 2006 – Several experimental models of cirrhosis have shown dysregulation of renal aquaporins in different phases of liver disease. We investigated the urinary excretion of both aquaporin‐1 and aquaporin‐2 in patients with cirrhosis at different stages of the disease.

Raúl J. Andrade, M. Isabel Lucena, Neil Kaplowitz, Beatriz García‐Muņoz, Yolanda Borraz, Ketevan Pachkoria, Miren García‐Cortés, M. Carmen Fernández, Gloria Pelaez, Luis Rodrigo, José A. Durán, Joan Costa, Ramón Planas, Anabel Barriocanal, Carlos Guarner, Manuel Romero‐Gomez, Teresa Muņoz‐Yagüe, Javier Salmerón, Ramón Hidalgo – 28 November 2006 – A chronic adverse reaction may occur in some instances of drug‐induced liver injury (DILI), even despite drug cessation.

Fabio Grizzi, Barbara Franceschini, Stefano Musardo, Eldo E. Frezza, Everardo Cobos, Maurizio Chiriva‐Internati – 28 November 2006

Frank V. Schiødt, George Ostapowicz, Natalie Murray, Raj Satyanarana, Atif Zaman, Santiago Munoz, William M. Lee – 28 November 2006 – Serum concentrations of alpha‐fetoprotein (AFP), variably elevated during liver injury, have been suggested to be of prognostic importance in acute liver failure (ALF), higher values being associated with improved outcome. Using a nephelometric assay, we measured AFP in sera obtained on admission from 206 patients prospectively enrolled in the US ALF Study, and on day 3 in 162 of these patients.

Jeffrey D. Duman, Stephen P. Johnson, James F. Trotter – 28 November 2006

Ryosuke Tateishi, Shuichiro Shiina, Haruhiko Yoshida, Takuma Teratani, Shuntaro Obi, Noriyo Yamashiki, Hideo Yoshida, Masatoshi Akamatsu, Takao Kawabe, Masao Omata – 28 November 2006 – Three tumor markers for hepatocellular carcinoma (HCC) are available in daily practice in Japan: alpha‐fetoprotein (AFP), des‐gamma‐carboxy prothrombin (DCP), and lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein (AFP‐L3).